Screening for Primary Aldosteronism by Mass Spectrometry Versus Immunoassay Measurements of Aldosterone: A Prospective Within-Patient Study.
Sybille FuldGeorgiana ConstantinescuChristina PamporakiMirko PeitzschManuel SchulzeJun YangLisa MüllerAleksander PrejbiszAndrzej JanuszewiczHanna RemdeLydia KürzingerUlrich DischingerMatthias ErnstSven GruberMartin ReinckeFelix BeuschleinJacques W M LendersGraeme EisenhoferPublished in: The journal of applied laboratory medicine (2024)
Mass spectrometry-based measurements of aldosterone for the ARR provide no clear diagnostic advantage over immunoassay-based measurements. Both approaches offer limited diagnostic accuracy for the ARR as a screening test. One solution is to employ the higher cutoffs to triage patients likely to have unilateral PA for further tests and possible adrenalectomy, while using the lower cutoffs to identify others for targeted medical therapy.German Clinical Trials Register ID: DRKS00017084.
Keyphrases
- mass spectrometry
- clinical trial
- end stage renal disease
- liquid chromatography
- emergency department
- ejection fraction
- healthcare
- high resolution
- angiotensin ii
- peritoneal dialysis
- prognostic factors
- high performance liquid chromatography
- capillary electrophoresis
- stem cells
- bone marrow
- study protocol
- drug delivery
- mesenchymal stem cells
- replacement therapy
- smoking cessation
- solid phase extraction